Surrogate Endpoints: Progression-Free vs Overall Survival

Evaluating clinical trial efficacy in late-stage oncology requires navigating the statistical trade-offs between rapid surrogate biomarkers and gold-standard survival metrics. Biostatistical methodology inside the FDA oncology accelerated approval PFE MRK playbook explores how surrogate endpoints dictate regulatory clearance speed.

While Overall Survival (OS)—the actual duration of patient life—is the ultimate therapeutic goal, verifying statistically significant OS gains requires massive patient cohorts followed over five to eight years. To accelerate access, regulators accept surrogate endpoints like Objective Response Rate (ORR) and Progression-Free Survival (PFS).

However, statistical decoupling remains a persistent hazard: many breakthrough oncology candidates demonstrating spectacular PFS extensions fail to produce statistically significant OS benefits during long-term follow-ups due to post-progression crossover therapy contamination and toxicity trade-offs.